400 related articles for article (PubMed ID: 11082458)
1. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A
J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458
[TBL] [Abstract][Full Text] [Related]
2. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
[TBL] [Abstract][Full Text] [Related]
3. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
[TBL] [Abstract][Full Text] [Related]
4. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
5. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin.
Dekeyne A; Millan MJ
Neuropharmacology; 2006 Sep; 51(4):718-26. PubMed ID: 16814817
[TBL] [Abstract][Full Text] [Related]
7. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
[TBL] [Abstract][Full Text] [Related]
8. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
Gobert A; Di Cara B; Cistarelli L; Millan MJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):338-46. PubMed ID: 12649387
[TBL] [Abstract][Full Text] [Related]
9. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
10. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
Gobert A; Billiras R; Cistarelli L; Millan MJ
J Neurosci Methods; 2004 Dec; 140(1-2):141-52. PubMed ID: 15589344
[TBL] [Abstract][Full Text] [Related]
11. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
Millan MJ; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet JM; Brocco M; Duqueyroix D; Nicolas JP; Boutin JA; Newman-Tancredi A
J Pharmacol Exp Ther; 2001 Jun; 297(3):876-87. PubMed ID: 11356907
[TBL] [Abstract][Full Text] [Related]
12. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
[TBL] [Abstract][Full Text] [Related]
13. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
14. Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline.
Millan MJ; Bervoets K; Rivet JM; Widdowson P; Renouard A; Le Marouille-Girardon S; Gobert A
J Pharmacol Exp Ther; 1994 Sep; 270(3):958-72. PubMed ID: 7932208
[TBL] [Abstract][Full Text] [Related]
15. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain.
Haddjeri N; Blier P; de Montigny C
J Pharmacol Exp Ther; 1996 May; 277(2):861-71. PubMed ID: 8627568
[TBL] [Abstract][Full Text] [Related]
16. In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse nucleus accumbens.
Ihalainen JA; Tanila H
J Neurochem; 2004 Oct; 91(1):49-56. PubMed ID: 15379886
[TBL] [Abstract][Full Text] [Related]
17. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat.
Seidel WF; Maze M; Dement WC; Edgar DM
J Pharmacol Exp Ther; 1995 Oct; 275(1):263-73. PubMed ID: 7562559
[TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine enhances the local anesthetic action of lidocaine via an alpha-2A adrenoceptor.
Yoshitomi T; Kohjitani A; Maeda S; Higuchi H; Shimada M; Miyawaki T
Anesth Analg; 2008 Jul; 107(1):96-101. PubMed ID: 18635472
[TBL] [Abstract][Full Text] [Related]
19. Noradrenergic modulation of serotonin release in rat dorsal and median raphé nuclei via alpha(1) and alpha(2A) adrenoceptors.
Hopwood SE; Stamford JA
Neuropharmacology; 2001 Sep; 41(4):433-42. PubMed ID: 11543763
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus.
Guiard BP; El Mansari M; Blier P
Mol Pharmacol; 2008 Nov; 74(5):1463-75. PubMed ID: 18703671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
